AI assistant
AGENUS INC — Director's Dealing 2010
May 4, 2010
34023_dirs_2010-05-04_a9fdc9bd-6069-425b-8e53-22d4afa9366c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ANTIGENICS INC /DE/ (AGEN)
CIK: 0001098972
Period of Report: 2010-05-03
Reporting Person: ARMEN GARO H (CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2010-05-03 | Common Stock | J | 10481 | $1.05 | Acquired | 1629155 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 12655941 | Indirect |
Footnotes
F1: Represents the issuance of stock for payment of 30% of Dr. Armen's base salary for the month of April 2010.
F2: Dr. Armen is the General Partner of Armen Partners LP. As of the date of this report Armen Partners owns a total of 1,507,667 shares of Antigenics Inc. common stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Armen Partners and disclaims beneficial ownership except to the extent of his pecuniary interest therein. Dr. Armen is also CEO, Chairman of the Board of Managers and a member of Antigenics Holdings LLC ("Holdings") which, as of the date of this report, owns 11,154,274 shares of Antigenics Inc. common stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Holdings and disclaims beneficial ownership except to the extent of his pecuniary interest therein.